Key points are not available for this paper at this time.
Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with traditional risk models often falling short in predicting individual susceptibility-especially among diverse populations. Recent advances in genomics have led to the development of polygenic risk scores (PRS), which aggregate the effects of multiple single nucleotide polymorphisms (SNPs) to estimate genetic predisposition to CVD. This review explores the scientific evolution, clinical relevance, and limitations of PRS in CVD prediction. Evidence shows that integrating PRS with conventional risk factors significantly improves risk stratification, aiding in early detection and personalized prevention strategies. Notably, ethnicity-specific PRS models are being developed to enhance predictive accuracy for non-European populations, including South Asians. Despite its promise, PRS implementation faces challenges, such as Eurocentric bias in genome-wide association studies (GWAS), limited accessibility in low- and middle-income countries, and ethical concerns regarding equity and data privacy. Future research should emphasize multi-ethnic datasets, integration with clinical and lifestyle data, and development of equitable policies. As PRS continues to be effective in refining cardiovascular risk stratification, its integration into public health frameworks could revolutionize risk assessment and drive the shift toward precision medicine. • PRS go beyond conventional clinical risk models to improve CVD prediction. • In a variety of populations, ethnicity-specific PRS increase accuracy. • Personalized prevention is supported by the integration of lifestyle data with PRS. • When combined, AI and genetics improve risk classification techniques. • Data inequity and Eurocentric bias are implementation obstacles.
Gupta et al. (Wed,) studied this question.